Combination treatment for advanced pancreatic or colorectal cancer with RAS mutation
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of two drugs for people with advanced pancreatic or colorectal cancer that has a specific genetic change called a RAS mutation and has not responded to standard treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced pancreatic or colorectal cancer that has not responded to standard therapy.
- Your tumor has a RAS mutation, as shown by genetic testing.
- You have at least one measurable tumor (can be seen on scans).
- You are able to take care of yourself (ECOG score 0 or 1) and expected to live at least 3 months.
- Your blood counts, liver, kidney, and heart functions are within acceptable levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a combination of two targeted drugs (tunlametinib and fruquintinib) for people with advanced colorectal cancer that has a RAS mutation and who have already tried at least two other treatments. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study tests a combination of drugs for people with advanced lung cancer that has a specific genetic change called KRAS. The treatment aims to shrink tumors or slow their growth after standard treatments have stopped working.
This study tests a combination of three drugs as a first treatment for advanced pancreatic cancer. It aims to see if this combination can shrink or control the cancer, and it checks safety and side effects.
This study tests a combination of two targeted pills (tunlametinib and vemurafenib) for people with metastatic colorectal cancer that has a specific gene change (BRAF V600E) and whose cancer has grown after at least one prior treatment. The goal is to see if this drug combination can shrink tumors or slow cancer growth.
This trial tests a combination of three drugs (tunlametinib, pucotenlimab, and hydroxychloroquine) for people with advanced melanoma that has a specific genetic change called NRAS. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a new oral targeted therapy (Tunlametinib) for people with advanced melanoma that has a specific gene change called NRAS. It's for those who have already tried immunotherapy and need another option.
Hear when a new Treatment for Advanced Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.